ProCE Banner Activity

Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

Podcast Episodes

Audio podcast with key clinical midyear highlights for gynecologic cancer from the 2024 SGO Annual Meeting on Women’s Cancer and the 2024 ASCO Annual Meeting. Listen to experts put new trial results into context and cover practical perspectives and takeaway points for your everyday practice. 

Released: August 05, 2024

Expiration: August 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Merck Sharp & Dohme, LLC

Seagen Inc.

Disclosure

Primary Author

Floor J Backes, MD

Professor
Director of Clinical Research
Division of Gynecologic Oncology
Associate Fellowship Director
Department of Obstetrics and Gynecology
The Ohio State University College of Medicine
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio

Floor J. Backes, MD: consultant/advisor/speaker: AstraZeneca, BioNTech, Daiichi Sankyo, Eisai, GlaxoSmithKline, ImmunoGen, Merck; researcher: AstraZeneca, ImmunoGen, Merck, Natera, Tempus.

Angeles Alvarez Secord, MD, MHSc

Professor with Tenure of Obstetrics and Gynecology
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
Director, Gynecologic Oncology Clinical Trials
Associate Director, Clinical Research, Gynecologic Oncology Program
Duke Cancer Institute
Duke University School of Medicine
Duke University Health System
Durham, North Carolina

Angeles Alvarez Secord, MD, MHSc: researcher: AbbVie, Aravive, AstraZeneca, Eisai, Ellipses Pharma, GlaxoSmithKline, I-Mab Biopharma, Karyopharm, Merck, Mersana, Myriad, OncoQuest/CanariaBio, Roche/Genentech, Seagen, VBL Therapeutics, Zentalis; consultant/advisor/speaker: AbbVie; individual publicly traded stock/stock options: Amgen, Johnson & Johnson.